Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337725

2024-01-01

Abstract:Figure S1. No association was found between RIP1 and MLKL expression and CRC patient survival.

What problem does this paper attempt to address?

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337716

2024-01-01

Abstract:Figure S4. Knockout or knockdown of RIP3, but not RIP1, suppressed necroptosis induced by 5-FU and other antimetabolites.
Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337719.v1

2024-01-01

Abstract:Figure S3. 5-FU and other antimetabolites induced necroptosis in p53-WT CRC cells expressing RIP3.
Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337713.v1

2024-01-01

Abstract:Figure S5. PUMA was induced by p53 and required for necroptosis induction in LoVo cells treated with antimetabolites.
Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337704

2024-01-01

Abstract:Figure S8. 5-FU-induced cell-surface translocation of calreticulin and DC phagocytosis of CRC cells are mediated by p53/PUMA/RIP3-dependent necroptosis.
Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337698

2024-01-01

Abstract:Table S1. Key reagents used in the experiments described in this manuscript are listed.
Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337722.v1

2024-01-01

Abstract:Figure S2. Analysis of 30 anticancer drugs revealed that 5-FU and Gemcitabine induced necroptosis in LoVo cells.
Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337695

2024-01-01

Abstract:Table S2. PCR primers used in the experiments described in this manuscript are listed.
Fig, S3 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fanxin Zeng,Xiao Chen,Weiyi Cui,Wei Wen,Fujian Lu,Xueting Sun,Dongwei Ma,Ye Yuan,Zezhong Li,Ning Hou,Hong Zhao,Xinyu Bi,Jianjun Zhao,Jianguo Zhou,Yan Zhang,Rui-Ping Xiao,Jianqiang Cai,Xiuqin Zhang

DOI: https://doi.org/10.1158/0008-5472.22420607

2023-01-01

Abstract:Figure S3. RIPK3 and p-MLKL is Decreased, while Caspase-8 is Increased in CRC. (A-D) Representative western blots and averaged data of RIPK3, p-MLKL, and Caspase 8 from normal and CRC tissue. Results are expressed as mean {plus minus} SEM. **p < 0.01, normal vs CRC (n=18).
Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fanxin Zeng,Xiao Chen,Weiyi Cui,Wei Wen,Fujian Lu,Xueting Sun,Dongwei Ma,Ye Yuan,Zezhong Li,Ning Hou,Hong Zhao,Xinyu Bi,Jianjun Zhao,Jianguo Zhou,Yan Zhang,Rui-Ping Xiao,Jianqiang Cai,Xiuqin Zhang

DOI: https://doi.org/10.1158/0008-5472.22420613.v1

2023-01-01

Abstract:Figure S1. High levels of RIPK1 Expression shows Poor Prognosis. (A) Relative levels of RIPK1 expression in CRC on different tumor stages (n = 40). (B) Relative levels of RIPK1 expression between alive (n=30) and death (n=8) in CRC.
PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

Lian Zhang,Yujiao He,Yi Jiang,Qi Wu,Yanchen Liu,Qingqiang Xie,Yuxiu Zou,Jiaqian Wu,Chundong Zhang,Zhongjun Zhou,Xiu-Wu Bian,Guoxiang Jin

DOI: https://doi.org/10.1038/s41419-023-05752-w

2023-04-02

Cell Death and Disease

Abstract:Necroptosis plays a double-edged sword role in necroptotic cancer cell death and tumor immune escape. How cancer orchestrates necroptosis with immune escape and tumor progression remains largely unclear. We found that RIP3, the central activator of necroptosis, was methylated by PRMT1 methyltransferase at the amino acid of RIP3 R486 in human and the conserved amino acid R479 in mouse. The methylation of RIP3 by PRMT1 inhibited the interaction of RIP3 with RIP1 to suppress RIP1-RIP3 necrosome complex, thereby blocking RIP3 phosphorylation and necroptosis activation. Moreover, the methylation-deficiency RIP3 mutant promoted necroptosis, immune escape and colon cancer progression due to increasing tumor infiltrated myeloid-derived immune suppressor cells (MDSC), while PRMT1 reverted the immune escape of RIP3 necroptotic colon cancer. Importantly, we generated a RIP3 R486 di-methylation specific antibody (RIP3 ADMA ). Clinical patient samples analysis revealed that the protein levels of PRMT1 and RIP3 ADMA were positively correlated in cancer tissues and both of them predicted the longer patient survival. Our study provides insights into the molecular mechanism of PRMT1-mediated RIP3 methylation in the regulation of necroptosis and colon cancer immunity, as well as reveals PRMT1 and RIP3 ADMA as the valuable prognosis markers of colon cancer.

cell biology
RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fanxin Zeng,Xiao Chen,Weiyi Cui,Wei Wen,Fujian Lu,Xueting Sun,Dongwei Ma,Ye Yuan,Zezhong Li,Ning Hou,Hong Zhao,Xinyu Bi,Jianjun Zhao,Jianguo Zhou,Yan Zhang,Rui-Ping Xiao,Jianqiang Cai,Xiuqin Zhang

DOI: https://doi.org/10.1158/0008-5472.can-17-3082

IF: 11.2

2018-01-01

Cancer Research

Abstract:AbstractThe receptor-interacting protein kinase 1 (RIPK1) is an essential signaling molecule in pathways for cell survival, apoptosis, and necroptosis. We report here that RIPK1 is upregulated in human colorectal cancer and promotes cell proliferation when overexpressed in a colon cancer cell line. RIPK1 interacts with mitochondrial Ca2+ uniporter (MCU) to promote proliferation by increasing mitochondrial Ca2+ uptake and energy metabolism. The ubiquitination site of RIPK1 (RIPK1-K377) was critical for this interaction with MCU and function in promoting cell proliferation. These findings identify the RIPK1-MCU pathway as a promising target to treat colorectal cancer.Significance: RIPK1-mediated cell proliferation through MCU is a central mechanism underlying colorectal cancer progression and may prove to be an important therapeutic target for colorectal cancer treatment. Cancer Res; 78(11); 2876–85. ©2018 AACR.
RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

Zhen-Yu Liu,Ming Zheng,Yi-Ming Li,Xin-Yu Fan,Jian-Chao Wang,Zhu-Chun Li,Hai-Jiao Yang,Jing-Min Yu,Jian Cui,Jian-Li Jiang,Juan Tang,Zhi-Nan Chen

DOI: https://doi.org/10.7150/thno.32126

IF: 11.6

2019-01-01

Theranostics

Abstract:Rationale: Necroptosis is a programmed form of non-apoptotic cell death that requires receptor-interacting protein 3 (RIP3). RIP3 has been shown to be relevant in multiple tumor types and has differential impact on tumor progression. We investigated whether RIP3 is involved in the progression of colitis-associated cancer (CAC) in mice.Methods: Tissues from colorectal cancer patients were examined for RIP3 expression. CAC was induced using azoxymethane (AOM) injection followed by dextran sodium sulfate (DSS) treatment in RIP3-deficient or wild-type mice. Colon tissues were collected and analyzed by Western blotting and gene expression profile analyses. Immune cell infiltration and CXCL1 expression were examined by flow cytometry and Real-time PCR, respectively.Results: RIP3 expression was upregulated in mouse CAC and human colon cancer. RIP3-deficient mice showed significantly attenuated colitis-associated tumorigenesis. Bone marrow transplantation experiments suggested that RIP3's function in hematopoietic cells primarily contributes to the phenotype. RIP3 supported epithelial proliferation and tumor growth via JNK signaling but had no effect on apoptosis. RIP3 deletion increased T cell accumulation and reduced infiltration by immunosuppressive subsets of myeloid cells during acute colitis and CAC. The immune-suppressive tumor microenvironment was dependent on RIP3-induced expression of the chemokine attractant CXCL1, and administration of recombinant CXCL1 during CAC restored tumorigenesis in Rip3-/- mice.Conclusion: Our results reveal an unexpected function of RIP3 in enhancing the proliferation of premalignant intestinal epithelial cells (IECs) and promoting myeloid cell-induced adaptive immune suppression. These two distinct mechanisms of RIP3-induced JNK and CXCL1 signalling contribute to CAC progression.

medicine, research & experimental
Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Heng Yang,Yuting Ma,Guo Chen,Heng Zhou,Takahiro Yamazaki,Christophe Klein,Federico Pietrocola,Erika Vacchelli,Sylvie Souquere,Allan Sauvat,Laurence Zitvogel,Oliver Kepp,Guido Kroemer

DOI: https://doi.org/10.1080/2162402x.2016.1149673

2016-01-01

OncoImmunology

Abstract:Chemotherapy can reinstate anticancer immunosurveillance through inducing tumor immunogenic cell death (ICD). Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL). Necroptotic cells featured biochemical hallmarks of ICD and stimulated anticancer immune responses in vivo. Chemotherapy normally killed Rip3(-/-) and Mlkl(-/-) tumor cells and normally induced caspase-3 activation in such cells, yet was unable to reduce their growth in vivo. RIP3 or MLKL deficiency abolished the capacity of dying cancer cells to elicit an immune response. This could be attributed to reduced release of ATP and high mobility group box 1 (HMGB1) by RIP3 and MLKL-deficient cells. Measures designed to compensate for deficient ATP and HMGB1 signaling restored the chemotherapeutic response of Rip3(-/-) and Mlkl(-/-) cancers. Altogether, these results suggest that RIP3 and MLKL can contribute to ICD signaling and tumor immunogenicity.
Prognostic significance and response to immune checkpoint inhibitors of RIPK3, MLKL and necroptosis in non-small cell lung cancer

Nattaya Duangthim,Thanpisit Lomphithak,Ryoko Saito-Koyama,Yasuhiro Miki,Chihiro Inoue,Ikuro Sato,Eisaku Miyauchi,Jiro Abe,Hironobu Sasano,Siriporn Jitkaew

DOI: https://doi.org/10.1038/s41598-024-72545-2

2024-09-16

Abstract:Lung cancer remains the leading cause of cancer death. Treatment with immune checkpoint inhibitor (ICI) alone or combination with chemotherapy served as first-line therapy in non-small cell lung cancer (NSCLC). However, only 20-50% of NSCLC patients respond to ICI. Necroptosis, an inflammatory form of cell death plays an important role in the regulation of tumor immune microenvironment which may affect prognosis and ICI response but its clinical significance in NSCLC patients has remained largely unknown. Therefore, we aimed to analyze the correlation between key necroptotic proteins and necroptosis and clinical outcomes, the status of tumor-infiltrating immune cells, and response to ICI in NSCLC patients. The expression of receptor-interacting protein kinase 3 (RIPK3), mixed lineage kinase domain-like protein (MLKL) and phosphorylated MLKL (pMLKL) were immunolocalized in 125 surgically resected NSCLC patients and 23 NSCLC patients administered with ICI therapy. CD8 + and FOXp3 + T cells and CD163 + M2 macrophages were also immunolocalized. High RIPK3 status was positively correlated with survival of the patients and RIPK3 turned out an independent favorable prognostic factor of the patients. RIPK3 was negatively correlated with CD8 + T cells, while MLKL positively correlated with CD163 + M2 macrophages, suggesting the possible involvement of RIPK3 and MLKL in formulating immunosuppressive microenvironment. In addition, high RIPK3 status tended to be associated with clinical resistance to ICI therapy (P-value = 0.057). Furthermore, NSCLC cells-expressing RIPK3 suppressed T cells response to ICI therapy in vitro. Therefore, RIPK3 and MLKL could induce an immunosuppressive microenvironment, resulting in low response to ICI therapy in NSCLC.
Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Yulai Zhou,Xiangyang Zhang,Yan Gao,Yinghui Peng,Ping Liu,Yihong Chen,Cao Guo,Gongping Deng,Yanhong Ouyang,Yan Zhang,Ying Han,Changjing Cai,Hong Shen,Le Gao,Shan Zeng

DOI: https://doi.org/10.1016/j.isci.2024.110318

IF: 5.8

2024-01-01

iScience

Abstract:Colorectal cancer (CRC) exhibits significant heterogeneity, impacting immunotherapy efficacy, particularly in immune desert subtypes. Neuromedin U receptor 1 (NMUR1) has been reported to perform a vital function in immunity and inflammation. Through comprehensive multi-omics analyses, we have systematically characterized NMUR1 across various tumors, assessing expression patterns, genetic alterations, prognostic significance, immune infiltration, and pathway associations at both the bulk sequencing and single-cell scales. Our findings demonstrate a positive correlation between NMUR1 and CD8+ T cell infiltration, with elevated NMUR1 levels in CD8+ T cells linked to improved immunotherapy outcomes in patients with CRC. Further, we have validated the NMUR1 expression signature in CRC cell lines and patient-derived tissues, revealing its interaction with key immune checkpoints, including lymphocyte activation gene 3 and cytotoxic T-lymphocyte-associated protein 4. Additionally, NMUR1 suppression enhances CRC cell proliferation and invasiveness. Our integrated analyses and experiments open new avenues for personalized immunotherapy strategies in CRC treatment.
Supplementary Figure 7C, D from Somatic Epigenetic Silencing of ripk3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Yinfei Tan,Eleonora Sementino,Mitchell Cheung,Suraj Peri,Craig W. Menges,Anna-Mariya Kukuyan,Ting Zhang,Vladimir Khazak,Lauren A. Fox,Eric A. Ross,Suresh Ramanathan,Suresh C. Jhanwar,Raja M. Flores,Siddharth Balachandran,Joseph R. Testa

DOI: https://doi.org/10.1158/1078-0432.22473981.v1

2023-01-01

Abstract:Expression of RIPK3 induced activation of MLKL and cell death, which was rescued by treatment with GSK'872. Transduction of M12 cells (C) and M22 cells (D) with lentivirus expressing shMLKL or shGFP and then selected for 72 h with puromycin. Stable cells expressing shMLKL or shGFP were then infected with WPI or WPI expressing RIPK3. Immunoblotting and cell viability were performed after 48 h to detect the activation of MLKL. Expression of RIPK3 induced necroptosis, which was rescued by MLKL knockdown.
Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

Kaylee Ermine,Dongshi Chen,Xinyan Lu,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1538-7445.am2023-2534

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Colorectal cancer (CRC) is a leading cause of cancer related deaths in the United States. CRC patients are often treated with the chemotherapeutic drug 5-fluorouracil (5-FU), but resistance often occurs. It is well-established that 5-FU induces apoptosis in cancer cells, but apoptosis inhibition does not block the anticancer effect of 5-FU, suggesting a role of non-apoptotic cell death. Necroptosis is a regulated form of necrosis controlled by Receptor-Interacting Protein kinase 1 (RIP1), RIP3, and Mixed Lineage Kinase domain-Like (MLKL), and its role in anticancer therapy remains unclear. TCGA RNAseq data show that RIP3 is significantly downregulated in primary CRC tumors, which is correlated with worse outcomes. RIP3 downregulation also occurs in established CRC cell lines and is associated with decreased 5-FU sensitivity. Therefore, we hypothesize that necroptosis may play a critical role in anticancer therapy and that restoring defective necroptosis may enhance therapeutic sensitivity. Our studies show that RIP3-expressing (RIP3+) CRC cells undergo both apoptosis and necroptosis in response to 5-FU. As expected, knock-out of RIP3 in RIP3+ CRC cells resulted in decreased 5-FU sensitivity, as well as abrogated necroptosis induction. Additionally, stable restoration of RIP3 in RIP3-silenced (RIP3-) CRC cells appeared to enhance 5-FU response, under conditions where apoptosis was inhibited. Furthermore, we explored alternative ways to induce necroptosis in RIP3-silenced cells. Together, our results suggest that necroptosis plays an important role in 5-FU-induced cell death in CRC. These results provide novel insights into the role of necroptosis in anticancer therapy in CRC, which could be used for development of improved therapies and personalized medicine based on RIP3 status. Citation Format: Kaylee Ermine, Dongshi Chen, Xinyan Lu, Jian Yu, Lin Zhang. Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2534.

oncology
SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhaobo Liu,Lang Chen,Yimin Fang,Pingping Ma,Xiaochong Wu,Hao Kong,Wenting Liao,Jingping Hong,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183972

2024-01-01

Abstract:Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.
Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer

Qiong Wang,Peipei Wang,Li Zhang,Mathewos Tessema,Lang Bai,Xiuling Xu,Qin Li,Xuelian Zheng,Bryanna Saxton,Wenshu Chen,Randy Willink,Zhiping Li,Lin Zhang,Steven A. Belinsky,Xia Wang,Bin Zhou,Yong Lin

DOI: https://doi.org/10.1016/j.tranon.2019.11.011

IF: 4.803

2020-01-01

Translational Oncology

Abstract:INTRODUCTION:The efficacy of chemotherapeutic agents in killing cancer cells is mainly attributed to the induction of apoptosis. However, the tremendous efforts on enhancing apoptosis-related mechanisms have only moderately improved lung cancer chemotherapy, suggesting that other cell death mechanisms such as necroptosis could be involved. In this study, we investigated the role of the necroptosis pathway in the responsiveness of nonsmall cell lung cancer (NSCLC) to chemotherapy.METHODS:In vitro cell culture and in vivo xenograft tumor therapy models and clinical sample studies are combined in studying the role of necroptosis in chemotherapy and mechanism of necroptosis suppression involving RIP3 expression regulation.RESULTS:While chemotherapeutic drugs were able to induce necroptotic cell death, this pathway was suppressed in lung cancer cells at least partly through downregulation of RIP3 expression. Ectopic RIP3 expression significantly sensitized lung cancer cells to the cytotoxicity of anticancer drugs such as cisplatin, etoposide, vincristine, and adriamycin. In addition, RIP3 suppression was associated with RIP3 promoter methylation, and demethylation partly restored RIP3 expression and increased chemotherapeutic-induced necroptotic cell death. In a xenograft tumor therapy model, ectopic RIP3 expression significantly sensitized anticancer activity of cisplatin in vivo. Furthermore, lower RIP3 expression was associated with worse chemotherapy response in NSCLC patients.CONCLUSION:Our results indicate that the necroptosis pathway is suppressed in lung cancer through RIP3 promoter methylation, and reactivating this pathway should be exploited for improving lung cancer chemotherapy.
RIPK4 driven by TP53 mutations promotes resistance to redox stress of CRC by phosphorylating MTHFD1

Long Yu,Sha Zhou,Yanbo Xu,Zongjin Zhang,Xiaoman Cheng,Chi Zhou,Weihao Li,Jiahua He,Qingjian Ou,Jiayi Qin,Yu-Jing Fang,Jianhong Peng,Jun-Zhong Lin,Bo Lin,Zhenlin Hou,Zhizhong Pan

DOI: https://doi.org/10.1101/2024.08.06.606759

2024-01-01

Abstract:This study investigates advanced colorectal cancer (CRC), focusing on its tendency for distant metastasis and chemotherapy resistance. It highlights the importance of PANoptosis, a cell death pathway, and the role of the Receptor-interacting serine/threonine-protein kinase (RIPK) family in tumor progression. RIPK4's tissue-specific functions in cancer cell behavior are emphasized, including its influence on invasion, migration, and oxidative stress resistance. The study reveals the critical balance of reactive oxygen species (ROS) in cancer cells, linked to antioxidant defenses and NADPH production for survival. A key finding is the connection between TP53 mutations in CRC and increased RIPK4 expression, which enhances MTHFD1 phosphorylation, boosts NADPH production, reduces ROS, and promotes resistance to PANoptosis, leading to metastasis. The research identifies the molecular basis of CRC metastasis, showing how RIPK4 regulates MTHFD1 to resist PANoptosis, offering new therapeutic targets for metastatic CRC and potential improvements in patient outcomes.

Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Fig, S3 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca<sup>2+</sup> Uptake and Promotes Colorectal Oncogenesis

PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Prognostic significance and response to immune checkpoint inhibitors of RIPK3, MLKL and necroptosis in non-small cell lung cancer

Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Supplementary Figure 7C, D from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer

RIPK4 driven by TP53 mutations promotes resistance to redox stress of CRC by phosphorylating MTHFD1

Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Fig, S3 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca&lt;sup&gt;2+&lt;/sup&gt; Uptake and Promotes Colorectal Oncogenesis

PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation

RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis

RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression

Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Prognostic significance and response to immune checkpoint inhibitors of RIPK3, MLKL and necroptosis in non-small cell lung cancer

Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Supplementary Figure 7C, D from Somatic Epigenetic Silencing of &lt;i&gt;ripk3&lt;/i&gt; Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer

RIPK4 driven by TP53 mutations promotes resistance to redox stress of CRC by phosphorylating MTHFD1

Fig, S1 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca<sup>2+</sup> Uptake and Promotes Colorectal Oncogenesis

Supplementary Figure 7C, D from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma